Novo Seeds co-leads Adcendo's EUR 51 Million Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers
Novo Seeds co-leads Adcendo's EUR 51 Million Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers - Novo Seeds played instrumental role in supporting Adcendo from inception - Plans to build a pipeline of ADCs directed at novel cancer targets COPENHAGEN, Denmark, April 29, 2021 /PRNewswire/ -- Novo Seeds, the early stage investment and company creation team of Novo Holdings, announced today an investment in Adcendo, a Danish biotech company which is developing antibody-drug conjugates (ADCs) for the treatment of cancers. The EUR 51 million (US$ 62 million) Ser...
Source: finanznachrichten.de